Biosimilar Clinical Trials: How Can Regulators Determine Waiver Early In Development?
FDA Public Workshop Discuss Key Issue For Biosimilar Sponsors
The evidence is growing that comparative efficacy trials may not be necessary for all biosimilars, but regulators said they need a standard for sponsors to meet in order to waive them.
